Related Experiment Video
Updated: Jan 9, 2026

Author Spotlight: Enhancing Success of Ultrasound-Guided Neuraxial Anesthesia in Cases with Difficult Anatomy
Published on: January 31, 2025
Liposomal Bupivacaine, Plain Bupivacaine, and Saline for Transversus Abdominis Plane Blocks: The CLEVELAND Randomized
Alparslan Turan1, Wael Ali Sakr Esa2, Jack Brooker3
1Center of Outcomes Research, Department of Anesthesiology, The University of Texas Health Science Center at Houston, Houston, Texas; Outcomes Research Consortium, Houston, Texas.
Background:
Enhanced Recovery After Surgery pathways recommend transversus abdominis plane (TAP) blocks, but their efficacy is controversial and limited by the duration of local anesthetics. Liposomal bupivacaine is commonly used in single-injection TAP blocks to extend analgesia, although its effectiveness remains unclear. Therefore, two coprimary hypotheses were tested: first, that opioid consumption during the initial 24 postoperative hours is higher with saline than plain bupivacaine or liposomal bupivacaine; and second, that opioid consumption between 24 to 48 h after surgery is comparable or greater with saline or plain bupivacaine than with liposomal bupivacaine.
Methods:
Patients having major abdominal surgery ( e.g. , colorectal, gynecological, hernia repairs) were enrolled and randomly assigned 1:1:1 to bilateral four-quadrant TAP blocks with liposomal bupivacaine (40 ml plain bupivacaine 0.25% with 20 ml liposomal bupivacaine and 20 ml saline), plain bupivacaine (50 ml plain bupivacaine 0.5% with 30 ml normal saline), and placebo (80 ml normal saline). Patient-controlled intravenous opioids were used as needed. Patients, clinicians who adjusted opioid analgesia, ward nurses who evaluated pain scores, and study investigators who evaluated local anesthetic effects were blinded to treatment groups.
Results:
In the modified intention-to-treat cohort of 261 patients, opioid requirements during the first 24 h were median [interquartile range] 26 [18, 48] milligram morphine equivalents (MME) for liposomal bupivacaine (n = 89), 33 [13, 75] MME for plain bupivacaine (n = 84), and 31 [17, 53] MME for placebo (n = 88). The estimated ratio of geometric means was 0.86 (97.7% CI, 0.60 to 1.24; P = 0.355) between liposomal bupivacaine and placebo groups, and 0.91 (97.7% CI, 0.63 to 1.32; P = 0.578) between plain bupivacaine and placebo groups. Opioid requirements between 24 and 48 h were also comparable across groups. Secondary outcomes, including time to sensation return, pain scores, and opioid requirements from 48 to 72 h, were similar across all groups, with no significant differences observed.
Conclusions:
Single-shot, four-quadrant TAP blocks performed with liposomal bupivacaine, plain bupivacaine, or normal saline before incision for various open and laparoscopic abdominal procedures resulted in similar postoperative opioid consumption and pain scores at 24, 48, and 72 h. Absence of early benefit suggests that routine preincision, single-shot TAP blocks in this mixed surgical population provide little analgesia.
More Related Videos
Related Concept Videos
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Local Anesthetics: Clinical Application as Spinal Anesthesia
Local Anesthetics: Clinical Application as Surface, Infiltration, and Conduction Block Anesthesia
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Local Anesthetics: Common Agents and Their Applications
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...
Depolarizing Blockers: Pharmocokinetics

